BoneSupport granted approval to market Cerament in India
BoneSupport recently announced it has received regulatory approval from the Central Drugs Standards Control Organization and its Medical Device Approval Committee to market Cerament in India.
An injectable, antibiotic-eluting bone void filler/substitute, Cerament is indicated for both osteomyelitis management and the enhancement of bone healing threatened by infection. The company plans to work with regional distributors to make Cerament available to numerous hospital groups throughout India, according to a company press release.
“The Cerament platform has a long-standing safety profile, and we are pleased to see this once again confirmed by India’s approval,” Lloyd Diamond, CEO of BoneSupport, said in the release. “Cerament is an important advancement in the management of bone infections, and we are proud to be at the forefront in addressing an unmet need to patients in India.”